- Home
- PCN vs PHAR Comparison
PCN vs PHAR Comparison
Compare PCN & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCN
- PHAR
- Stock Information
- Founded
- PCN 2001
- PHAR 1988
- Country
- PCN United States
- PHAR Netherlands
- Employees
- PCN N/A
- PHAR N/A
- Industry
- PCN Investment Managers
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- PCN Finance
- PHAR Health Care
- Exchange
- PCN Nasdaq
- PHAR Nasdaq
- Market Cap
- PCN 800.4M
- PHAR 718.1M
- IPO Year
- PCN N/A
- PHAR N/A
- Fundamental
- Price
- PCN $12.57
- PHAR $10.45
- Analyst Decision
- PCN
- PHAR Strong Buy
- Analyst Count
- PCN 0
- PHAR 3
- Target Price
- PCN N/A
- PHAR $30.00
- AVG Volume (30 Days)
- PCN 218.7K
- PHAR 2.6K
- Earning Date
- PCN 01-01-0001
- PHAR 07-31-2025
- Dividend Yield
- PCN 9.73%
- PHAR N/A
- EPS Growth
- PCN N/A
- PHAR N/A
- EPS
- PCN N/A
- PHAR N/A
- Revenue
- PCN N/A
- PHAR $320,708,000.00
- Revenue This Year
- PCN N/A
- PHAR $13.31
- Revenue Next Year
- PCN N/A
- PHAR $7.68
- P/E Ratio
- PCN N/A
- PHAR N/A
- Revenue Growth
- PCN N/A
- PHAR 24.13
- 52 Week Low
- PCN $10.70
- PHAR $6.65
- 52 Week High
- PCN $14.48
- PHAR $12.61
- Technical
- Relative Strength Index (RSI)
- PCN 40.89
- PHAR 47.51
- Support Level
- PCN $12.46
- PHAR $10.41
- Resistance Level
- PCN $12.61
- PHAR $11.50
- Average True Range (ATR)
- PCN 0.09
- PHAR 0.32
- MACD
- PCN -0.02
- PHAR -0.17
- Stochastic Oscillator
- PCN 30.00
- PHAR 2.26
About PCN Pimco Corporate & Income Strategy Fund
PIMCO Corporate & Income Strategy Fund is a closed-end management investment company. Its objective is to seek high current income with capital appreciation as a secondary objective. It invests in corporate bonds and notes, non-agency mortgage-backed securities, asset-backed securities, short-term instruments, and others.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.